BRPI0812040A2 - Indicações para terapia de anti-il-i-beta - Google Patents

Indicações para terapia de anti-il-i-beta

Info

Publication number: BRPI0812040A2
Authority: BR; Brazil
Prior art keywords: indications; beta therapy; beta; therapy
Prior art date: 2007-05-29

Application number

BRPI0812040-4A2A

Other languages

English (en)

Inventor

Hermann Gram

Thomas Jung

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-28

Publication date

2014-10-21

2008-05-28 Application filed by Novartis Ag filed Critical Novartis Ag

2014-10-21 Publication of BRPI0812040A2 publication Critical patent/BRPI0812040A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0812040-4A2A 2007-05-29 2008-05-28 Indicações para terapia de anti-il-i-beta BRPI0812040A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07109084		2007-05-29
PCT/EP2008/056520 WO2008145664A1 (en)	2007-05-29	2008-05-28	New indications for anti- il-i-beta therapy

Publications (1)

Publication Number	Publication Date
BRPI0812040A2 true BRPI0812040A2 (pt)	2014-10-21

Family

ID=38626983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812040-4A2A BRPI0812040A2 (pt)	2007-05-29	2008-05-28	Indicações para terapia de anti-il-i-beta

Country Status (11)

Country	Link
US (7)	US8282922B2 (pt)
EP (5)	EP3406263A1 (pt)
JP (7)	JP2010528086A (pt)
KR (7)	KR20180032687A (pt)
CN (2)	CN104873972A (pt)
AU (1)	AU2008257520B2 (pt)
BR (1)	BRPI0812040A2 (pt)
CA (7)	CA3156905C (pt)
MX (1)	MX2009012948A (pt)
RU (2)	RU2009148597A (pt)
WO (1)	WO2008145664A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG187231A1 (en)	2010-07-29	2013-02-28	Eleven Biotherapeutics Inc	Chimeric il-1 receptor type i agonists and antagonists
CN104474546A (zh) *	2010-08-13	2015-04-01	弗·哈夫曼-拉罗切有限公司	用于疾病治疗的针对IL-1β和IL-18的抗体
EP2614085B1 (en)	2010-09-10	2016-04-20	Apexigen, Inc.	Anti-il-1 beta antibodies and methods of use
CN103059136A (zh) *	2012-12-24	2013-04-24	浙江大学	抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
CN107693781B (zh)	2013-03-13	2021-11-09	巴扎德制药公司	用于眼部递送的嵌合细胞因子制剂
JP6456015B2 (ja) *	2013-07-19	2019-01-23	国立大学法人三重大学	閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN118175299A (zh)	2018-04-02	2024-06-11	Lg电子株式会社	解码设备、编码设备和发送设备
CN110818793A (zh)	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
EP4093430A4 (en) *	2020-01-21	2024-01-24	Tavotek Biotherapeutics (Hong Kong) Limited	AGENTS THAT INTERFERE WITH IL-1 RECEPTOR SIGNALING?
IL301263A (en)	2020-11-18	2023-05-01	Novartis Ag	BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
WO2024102997A1 (en)	2022-11-11	2024-05-16	Peterson Jeff R	Gout flare prevention methods using il-1β inhibitors
US12269875B2 (en) *	2023-08-03	2025-04-08	Jeff R. Peterson	Gout flare prevention methods using IL-1BETA blockers
WO2025071159A1 (ko)	2023-09-27	2025-04-03	주식회사 엘지에너지솔루션	전고체 전지용 양극 및 이를 포함하는 전고체 전지
JP2025165487A (ja)	2024-04-23	2025-11-05	セイコーエプソン株式会社	シート製造装置

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
CA2165919A1 (en)	1994-12-26	1996-06-27	Koichi Katsuyama	Agents for inhibiting the production of il-1.beta. and the release of tnf.
US5643915A (en) *	1995-06-06	1997-07-01	Andrulis Pharmaceuticals Corp.	Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
AU783158B2 (en)	1999-08-24	2005-09-29	Ariad Pharmaceuticals, Inc.	28-epirapalogs
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
EP2241328A1 (en) *	2000-05-12	2010-10-20	Immunex Corporation	Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
SG159378A1 (en)	2000-11-07	2010-03-30	Novartis Ag	Indolylmaleimide derivatives as protein kinase c inhibitors
BR0307544A (pt)	2002-02-01	2004-12-07	Ariad Gene Therapeutics Inc	Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
PE20040079A1 (es)	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
AU2003255851B2 (en)	2002-07-08	2009-07-23	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	New compounds, compositions and methods for treatment of inflammatory diseases and conditions
KR20110017020A (ko) *	2002-10-17	2011-02-18	젠맵 에이/에스	Ｃｄ20에 대한 인간 모노클로날 항체
WO2004052359A1 (en)	2002-12-09	2004-06-24	The Board Of Regents Of The University Of Texas System	Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
US20080207613A1 (en)	2004-01-12	2008-08-28	Cytopia Research Pty Ltd	Selective Kinase Inhibitors
AU2005216298B2 (en) *	2004-02-26	2010-09-02	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
AU2005249570B2 (en) *	2004-06-04	2011-06-16	Regeneron Pharmaceuticals, Inc.	Methods of using IL-1 antagonists to treat autoinflammatory disease
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
EP1851245B1 (en) *	2005-01-26	2012-10-10	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
ES2569917T3 (es) *	2005-06-21	2016-05-13	Xoma (Us) Llc	Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
EP1940880A2 (en) *	2005-10-14	2008-07-09	Novo Nordisk A/S	Treating diabetes using inhibitors of il-1
EP2848258B1 (en) *	2005-10-26	2017-12-13	Novartis AG	Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
EP3124045A3 (en) *	2006-12-20	2017-05-03	Xoma (Us) Llc	Treatment of il-1 beta related diseases

2008
- 2008-05-28 EP EP18177247.6A patent/EP3406263A1/en not_active Withdrawn
- 2008-05-28 CA CA3156905A patent/CA3156905C/en active Active
- 2008-05-28 RU RU2009148597/15A patent/RU2009148597A/ru unknown
- 2008-05-28 CA CA2687499A patent/CA2687499C/en active Active
- 2008-05-28 WO PCT/EP2008/056520 patent/WO2008145664A1/en not_active Ceased
- 2008-05-28 BR BRPI0812040-4A2A patent/BRPI0812040A2/pt not_active Application Discontinuation
- 2008-05-28 KR KR1020187008103A patent/KR20180032687A/ko not_active Ceased
- 2008-05-28 EP EP12158373A patent/EP2468301A1/en not_active Ceased
- 2008-05-28 CA CA3213888A patent/CA3213888A1/en active Pending
- 2008-05-28 KR KR1020167002268A patent/KR20160017119A/ko not_active Ceased
- 2008-05-28 KR KR1020097026864A patent/KR101591533B1/ko active Active
- 2008-05-28 EP EP12158424A patent/EP2468302A1/en not_active Ceased
- 2008-05-28 CA CA2947947A patent/CA2947947C/en active Active
- 2008-05-28 CN CN201510324201.1A patent/CN104873972A/zh active Pending
- 2008-05-28 KR KR1020227012190A patent/KR102606597B1/ko active Active
- 2008-05-28 KR KR1020237029637A patent/KR102824865B1/ko active Active
- 2008-05-28 EP EP22196860.5A patent/EP4177268A3/en active Pending
- 2008-05-28 US US12/601,280 patent/US8282922B2/en active Active
- 2008-05-28 JP JP2010509810A patent/JP2010528086A/ja active Pending
- 2008-05-28 CA CA3080328A patent/CA3080328C/en active Active
- 2008-05-28 KR KR1020217011722A patent/KR20210047376A/ko not_active Ceased
- 2008-05-28 EP EP08760116A patent/EP2152308A1/en not_active Ceased
- 2008-05-28 AU AU2008257520A patent/AU2008257520B2/en active Active
- 2008-05-28 KR KR1020197005950A patent/KR20190025056A/ko not_active Ceased
- 2008-05-28 CA CA3030662A patent/CA3030662C/en active Active
- 2008-05-28 CN CN200880018047A patent/CN101678104A/zh active Pending
- 2008-05-28 MX MX2009012948A patent/MX2009012948A/es not_active Application Discontinuation
- 2008-05-28 CA CA2993565A patent/CA2993565C/en active Active
2012
- 2012-08-17 US US13/587,978 patent/US8524667B2/en active Active
2013
- 2013-07-31 US US13/955,673 patent/US9168298B2/en active Active
2014
- 2014-01-15 RU RU2014101207A patent/RU2698208C9/ru active
- 2014-07-03 JP JP2014137895A patent/JP6454098B2/ja active Active
2015
- 2015-09-22 US US14/861,191 patent/US9534047B2/en active Active
2016
- 2016-07-01 JP JP2016131312A patent/JP2016183187A/ja not_active Withdrawn
- 2016-11-23 US US15/359,784 patent/US10106604B2/en not_active Expired - Fee Related
2018
- 2018-03-07 JP JP2018040956A patent/JP6685339B2/ja active Active
- 2018-09-13 US US16/129,921 patent/US10968272B2/en active Active
2020
- 2020-03-30 JP JP2020060389A patent/JP7069242B2/ja active Active
2021
- 2021-02-26 US US17/186,301 patent/US20210179705A1/en not_active Abandoned
2022
- 2022-05-02 JP JP2022075912A patent/JP7459166B2/ja active Active
2024
- 2024-03-18 JP JP2024042358A patent/JP2024069547A/ja active Pending

Also Published As

Publication number	Publication date
CA2947947C (en)	2018-03-06
US9168298B2 (en)	2015-10-27
RU2014101207A (ru)	2015-07-20
CA2687499A1 (en)	2008-12-04
JP7069242B2 (ja)	2022-05-17
US20160002328A1 (en)	2016-01-07
RU2019125748A (ru)	2021-02-15
JP6685339B2 (ja)	2020-04-22
US8282922B2 (en)	2012-10-09
CA3156905A1 (en)	2008-12-04
EP2152308A1 (en)	2010-02-17
JP6454098B2 (ja)	2019-01-16
US10968272B2 (en)	2021-04-06
CA2687499C (en)	2017-11-28
JP2020105220A (ja)	2020-07-09
EP4177268A2 (en)	2023-05-10
CA3080328A1 (en)	2008-12-04
KR20220050240A (ko)	2022-04-22
WO2008145664A1 (en)	2008-12-04
RU2698208C2 (ru)	2019-08-23
RU2698208C9 (ru)	2019-10-11
CN101678104A (zh)	2010-03-24
EP4177268A3 (en)	2023-05-24
CA2993565C (en)	2019-04-02
MX2009012948A (es)	2009-12-14
AU2008257520A1 (en)	2008-12-04
CA3030662A1 (en)	2008-12-04
US10106604B2 (en)	2018-10-23
US8524667B2 (en)	2013-09-03
CA2993565A1 (en)	2008-12-04
KR20160017119A (ko)	2016-02-15
CA3030662C (en)	2020-06-30
KR102606597B1 (ko)	2023-11-29
RU2019125748A3 (pt)	2022-02-11
US20120321642A1 (en)	2012-12-20
KR102824865B1 (ko)	2025-06-26
KR101591533B1 (ko)	2016-02-03
US20170073411A1 (en)	2017-03-16
JP2010528086A (ja)	2010-08-19
CA3156905C (en)	2023-11-07
JP2014205706A (ja)	2014-10-30
KR20180032687A (ko)	2018-03-30
US20130309241A1 (en)	2013-11-21
CN104873972A (zh)	2015-09-02
JP7459166B2 (ja)	2024-04-01
JP2022093640A (ja)	2022-06-23
EP2468301A1 (en)	2012-06-27
CA3080328C (en)	2022-06-21
JP2018104462A (ja)	2018-07-05
KR20230130763A (ko)	2023-09-12
RU2009148597A (ru)	2011-07-10
KR20190025056A (ko)	2019-03-08
KR20210047376A (ko)	2021-04-29
CA2947947A1 (en)	2008-12-04
JP2024069547A (ja)	2024-05-21
JP2016183187A (ja)	2016-10-20
US20100166750A1 (en)	2010-07-01
US20190002554A1 (en)	2019-01-03
CA3213888A1 (en)	2008-12-04
US20210179705A1 (en)	2021-06-17
EP2468302A1 (en)	2012-06-27
US9534047B2 (en)	2017-01-03
AU2008257520B2 (en)	2012-04-05
EP3406263A1 (en)	2018-11-28
KR20100022082A (ko)	2010-02-26

Legal Events

Date	Code	Title	Description
2015-10-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-23	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-02-05	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-07-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-05-26	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-08-11	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2022-07-12	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI0813497A2 (pt)	2008-12-31	Tampão antisséptico com cobertura para linha
BRPI0818380A2 (pt)	2014-10-07	Combinação de herbicida-protetor
PT2515855E (pt)	2014-06-11	Terapêutica de combinação para dpoc
PA8805201A1 (es)	2010-02-12	Piperidinas heteroaril-sustituidas
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
AT505058A3 (de)	2008-12-15	Türschliesssystem
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0807984A2 (pt)	2014-06-24	Unidade de distribuição
EP2227553A4 (en)	2011-01-19	Lac expression system
BRPI0918508A2 (pt)	2015-12-08	orto-aminoanilidas para o tratamento de câncer
BRPI0812105A2 (pt)	2014-11-25	Neramexano para o tratamento de nistagmo
ES1065457Y (es)	2007-11-16	Dispositivo de amortiguacion para quads
ES1064720Y (es)	2007-07-16	Guia para persiana
ES1064958Y (es)	2007-08-16	Soporte para mechero
ES1065835Y (es)	2008-02-16	Caperuza para cetreria
ES1066267Y (es)	2008-04-01	Soporte para protesis
DE112007003477A5 (de)	2010-01-28	Schutzgerät
DE112007003228A5 (de)	2009-12-24	Temperiervorrichtung
ES1066084Y (es)	2008-03-16	Poliedro tetraedro desmontable
AT9563U3 (de)	2008-05-15	Wirbelsäulenzuggurtung
AT504425B1 (de)	2008-05-15	Portioniersteuerung
ES1063735Y (es)	2007-03-01	Testero para persiana
ES1065263Y (es)	2007-10-16	Captafaros para bionda
ES1062659Y (es)	2006-10-01	Estructura para cubiertas